Aveo RCC compound trends toward detrimental survival effect, again
Despite announcing plans to submit an NDA to FDA for its renal cell carcinoma compound in about six months, Aveo Pharmaceuticals Inc. (NASDAQ:AVEO) lost $0.51 (20%) to $2.03 on Tuesday after reporting preliminary data late